Factors Governing P-Glycoprotein-Mediated Drug–Drug Interactions at the Blood–Brain Barrier Measured with Positron Emission Tomography-Reference-Cited by-同舟云学术

Factors Governing P-Glycoprotein-Mediated Drug–Drug Interactions at the Blood–Brain Barrier Measured with Positron Emission Tomography

Published:2015-08-03 Issue:9 Volume:12 Page:3214-3225
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Wanek Thomas¹,Römermann Kerstin²³,Mairinger Severin¹,Stanek Johann¹³,Sauberer Michael¹,Filip Thomas¹,Traxl Alexander¹,Kuntner Claudia¹,Pahnke Jens⁴⁵,Bauer Florian⁶,Erker Thomas⁶,Löscher Wolfgang²,Müller Markus³,Langer Oliver¹³

Affiliation:

1. Health & Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria

2. Department of Pharmacology, Toxicology & Pharmacy, University of Veterinary Medicine Hannover, Hannover, Germany

3. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

4. Department of Neuro-/Pathology, University of Oslo (UiO) and Oslo University Hospital (OUS), Oslo, Norway

5. Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany

6. Department of Medicinal Chemistry, University of Vienna, Vienna, Austria

Funder

Austrian Science Fund

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.5b00168

Reference53 articles.

1. Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position

2. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

3. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

4. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

5. Development of a P-Glycoprotein Knockout Model in Rodents to Define Species Differences in its Functional Effect at the Blood–brain Barrier

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long acting tariquidar loaded stearic acid-modified hydroxyapatite enhances brain penetration and antitumor effect of temozolomide;European Journal of Pharmaceutics and Biopharmaceutics;2024-04

2. P-glycoproteins in the Pathology and Treatment of Alzheimer's Disease;Letters in Drug Design & Discovery;2024-02-28

3. Performance and Sensitivity of [^99mTc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver;Molecular Pharmaceutics;2024-01-16

4. [¹¹C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier;Journal of Cerebral Blood Flow & Metabolism;2023-09-20

5. Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function;Journal of Controlled Release;2023-09